Alternative MYB Promoter Activity Is a Potential Prognostic Biomarker in Head and Neck Adenoid Cystic Carcinoma

Abstract excerpt

BACKGROUND: Adenoid cystic carcinoma (ACC) is an aggressive therapy-resistant head and neck cancer with a high frequency of local recurrences and distant metastases. Activation of the MYB gene, encoding an oncogenic master transcription factor, is the key genomic hallmark of ACC and a potential therapeutic target. Here, we have investigated the clinical significance of alternative MYB promoter (MYB TSS2)...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Head and Neck Cancer Studies
• Share to Head and Neck Surgical Oncology
• Share to Salivary Gland Tumors Diagnosis and Treatment